

# CONTENTS

Publisher's Note . . . . .	vii
Introduction . . . . .	ix
Contributors . . . . .	xi

---

## Scope of Prescription Drugs Abused

<b>and Misused . . . . .</b>	<b>1</b>
Addiction . . . . .	3
Age and addiction . . . . .	5
Celebrities and substance misuse . . . . .	9
Dependence . . . . .	12
Dopamine and addiction . . . . .	14
Drug misuse and addiction: Overview . . . . .	16
Drug misuse and addiction: In depth . . . . .	18
Economic impact of addiction . . . . .	22
Families and substance misuse . . . . .	27
Legislation and substance misuse . . . . .	31
Marriage/partnership and substance misuse . . . . .	34
Men and substance misuse . . . . .	36
Narcotics' effects on the body . . . . .	39
Newborn addicts . . . . .	42
Opioid epidemic . . . . .	45
Prescription drug abuse versus misuse . . . . .	49
Prescription drug addiction: In depth . . . . .	52
Stigma of addiction . . . . .	56
Trends and statistics: Prescription drug misuse . . . . .	58
Veterans and addiction . . . . .	61
Women and substance misuse . . . . .	63
Work issues and substance misuse . . . . .	66

---

## Classes of Drugs Commonly Abused

<b>or Misused . . . . .</b>	<b>71</b>
ADHD medications . . . . .	73
Amphetamine misuse . . . . .	76
Anabolic steroids . . . . .	78
Analgesics . . . . .	80
Anti-inflammatory drugs . . . . .	82
Anti-nausea medications . . . . .	85
Antipsychotic drugs . . . . .	88
Anxiety medication misuse . . . . .	91
Benzodiazepine misuse . . . . .	93
Cannabinoids . . . . .	96
Corticosteroids . . . . .	99
Depressants misuse . . . . .	102
Emetic misuse . . . . .	104

Laxative misuse . . . . .	106
Narcotics misuse . . . . .	108
NMDA receptor antagonists . . . . .	110
Opioid misuse . . . . .	113
Over-the-counter drug misuse . . . . .	114
Painkiller misuse . . . . .	118
Routes of administration for drugs of misuse . . . . .	122
Sedative-hypnotic misuse . . . . .	124
Sexual stimulant misuse . . . . .	127
Sleeping pills addiction . . . . .	128
Stimulant misuse . . . . .	132

---

## Prevention and Recognition of Potential

<b>Abuse or Misuse . . . . .</b>	<b>135</b>
Addictive personality and behaviors . . . . .	137
Cancer and substance misuse . . . . .	140
Center for Substance Abuse Prevention (CSAP) . . . . .	143
Controlled Substances Act . . . . .	144
D.A.R.E. (Drug Abuse Resistance Education) . . . . .	146
Drug interactions . . . . .	148
Drug testing . . . . .	150
Education about substance misuse . . . . .	154
Heart attacks and substance misuse . . . . .	157
Models of addiction . . . . .	159
Pain management and non-medication interventions . . . . .	161
Parenting and substance misuse . . . . .	165
Pharmacology and the role of the pharmacist . . . . .	168
Prescription drug abuse and misuse prevention . . . . .	174
Recognizing symptoms of abuse and misuse . . . . .	176
Schools and substance misuse . . . . .	178
Self-medication . . . . .	182
Socioeconomic status and addiction . . . . .	183
Stress and drug misuse . . . . .	186
Substance Abuse and Mental Health Services Administration . . . . .	187
Symptoms of substance misuse . . . . .	189
War on Drugs . . . . .	191

---

<b>Treatment of Prescription Drug Addiction . . . . .</b>	<b>193</b>
Alternative therapies for addiction . . . . .	195
Behavioral therapies for addiction . . . . .	198
Betty Ford Center, The Hazelden Betty Ford Foundation . . . . .	201

Biofeedback . . . . .	203	Librium . . . . .	263
Detoxification and substance misuse . . . . .	206	Medical marijuana . . . . .	264
Intervention . . . . .	208	Methadone . . . . .	267
Just Say No campaign . . . . .	212	Morphine . . . . .	268
Meditation, alcohol, substance misuse and addictions . . . . .	214	Naloxone . . . . .	270
Narcotics Anonymous . . . . .	216	Naltrexone . . . . .	271
Overdose . . . . .	218	Narcotics . . . . .	272
Science of addiction . . . . .	224	Nitrazepam . . . . .	277
Substance misuse and treatment. . . . .	226	Over-the-counter (OTC) drugs. . . . .	279
Twelve-step programs . . . . .	229	Over-the-counter (OTC) drugs: Cautions and precautions . . . . .	283
Twelve-step programs for family and friends . . .	233	Oxycodone . . . . .	286
Withdrawal . . . . .	235	Pentazocine, butorphanol, nalbuphine. . . . .	287
<b>Specific Drugs and Drug Classes . . . . .</b>	<b>237</b>	Pregabalin . . . . .	289
Baclofen . . . . .	239	Prescription NSAIDs . . . . .	290
Cannabidiol (CBD) and THC. . . . .	240	Ritalin . . . . .	292
Carbamazepine. . . . .	242	Sildenafil. . . . .	293
Codeine. . . . .	247	Soma . . . . .	295
Cyclooxygenase-2 (COX-2) inhibitors . . . . .	248	Suboxone . . . . .	296
Decongestants. . . . .	249	Temazepam. . . . .	297
Dextroamphetamine. . . . .	251	Tramadol. . . . .	298
Dextromethorphan. . . . .	252	Valium . . . . .	300
Ephedrine . . . . .	253	Vicodin and Norco . . . . .	301
Fentanyl. . . . .	254	Bibliography . . . . .	305
Gabapentin . . . . .	256	Glossary. . . . .	337
Hydrocodone . . . . .	259	Organizations . . . . .	343
Insulin. . . . .	260	Subject Index . . . . .	349